Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Runben Biotechnology Co., Ltd. on November 5, 2025, with no resolutions being rejected [1][2]. - The meeting was convened by the board of directors and chaired by Mr. Zhao Guiqin, with a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][3]. - All six current directors attended the meeting, along with the board secretary [3]. Group 2 - One of the key resolutions passed was the reappointment of the accounting firm, which was approved by the shareholders [4]. - The meeting was witnessed by Guangdong Guangxin Junda Law Firm, with lawyers Zhang Wei and Ma Xiaoxi confirming the legality and validity of the meeting's procedures and resolutions [5].

广东广信君达律师事务所 关于润本生物技术股份有限公司 2025 年第三次临时股东会的法律意见书 致：润本生物技术股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托，指派张伟、马小希律师（以下简称"本律师"）出席了公司于 2025 年 11 月 5 日（星期三）下午 15:30 在广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼公司 会议室召开的 2025 年第三次临时股东会（以下简称"本次股东会"），并依据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》、《上海证券交易所股 票上市规则》等中国现行法律、法规和其它规范性法律文件（以下合称"法律法规"）以及《润 本生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，就本次股东会的召集 和召开程序、出席会议人员的资格和召集人资格、表决程序和表决结果等相关事宜出具法律意 见。 为出具本法律意见书，本律师听取了公司就有关事实的陈述和说明，审查了公司提供的相 关文件，包括但不限于： 1. 公司章程； 2. 第二届董事会第十次会议决议公告； 3. 公司于 2025 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-047 润本生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 5 日 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，公司董事长赵贵钦先生主持。本次股东会采 用现场投票和网络投票相结合的方式召开并表决，会议的召开及表决符合《公司 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：《关于续聘会计师事务所的议案》 审议结果：通过 表决情况： (二)股东会召开的地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信大 厦 40 楼润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有 ...

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].

Market Overview - The personal care products sector experienced a decline of 0.95% on November 4, with Dengkang Oral Care leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances include: - Liangmian Needle (600249) rose by 1.72% to close at 6.49, with a trading volume of 321,100 shares and a turnover of 210 million yuan [1] - Zhongshun Jiesang (002511) increased by 0.25% to 8.09, with a trading volume of 144,000 shares [1] - Dengkang Oral Care (001328) fell by 3.17% to 36.65, with a trading volume of 21,900 shares and a turnover of approximately 80.70 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 41.58 million yuan from institutional investors and 41.59 million yuan from speculative funds, while retail investors had a net inflow of 83.17 million yuan [2] - Detailed capital flow for selected stocks indicates: - Yanjing Co. (300658) had a net inflow of over 9.99 million yuan from institutional investors [3] - Dengkang Oral Care (001328) experienced a net outflow of 2.68 million yuan from institutional investors [3] - The overall trend shows a mixed response from different investor categories, with retail investors showing a positive net inflow across several stocks [3]

Market Overview - The personal care products sector experienced a decline of 0.38% on November 3, with Yiyi Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance - Notable gainers in the personal care sector included: - Yanjing Co., Ltd. with a closing price of 9.07, up 4.25% [1] - Liangmian Needle with a closing price of 6.38, up 2.90% [1] - Jieya Co., Ltd. with a closing price of 32.98, up 2.42% [1] - Conversely, Yiyi Co., Ltd. saw a significant decline, closing at 29.34, down 4.37% [2] - Other notable decliners included: - Zhenjian Medical with a closing price of 40.91, down 0.94% [2] - Beijia Clean with a closing price of 30.80, down 0.61% [2] Capital Flow Analysis - The personal care products sector saw a net outflow of 47.21 million yuan from institutional investors, while retail investors contributed a net inflow of 24.22 million yuan [2] - The capital flow for specific stocks showed: - Yanjing Co., Ltd. had a net inflow of 8.22 million yuan from institutional investors [3] - Liangmian Needle experienced a net inflow of 2.80 million yuan from retail investors [3] - Zhenjian Medical faced a net outflow of 8.66 million yuan from institutional investors [3]

Industry Overview - In 2025, social consumption and retail enterprises are slowly recovering, with segments like gold jewelry benefiting from high gold prices, while cosmetics and medical aesthetics face intense competition and the rise of domestic brands. Notably, "emotional consumption" remains a key indicator of market vitality [2][8]. Segment Analysis Gold Jewelry - The industry has undergone significant changes, with high gold prices and declining wedding demand affecting traditional brand competitiveness. The rise of emotional consumption and social media marketing has led to the emergence of new brands with differentiated products and consumer insights. Opportunities are seen in high-end Chinese gold and trendy gold segments [3][25]. Retail E-commerce - Offline retailers are transforming from selling "goods" to offering "services and experiences," leveraging their advantages to attract traffic back. Online cross-border e-commerce is expected to enter a demand improvement phase with the easing of interest rates, further enhanced by AI integration [3][19]. Cosmetics - Domestic brands are capitalizing on cultural roots and emotional value to increase market share. Innovations in product safety and emotional value are key, with opportunities in regional and technological narratives, sensitive skin anti-aging, and domestic color cosmetics [3][85]. Medical Aesthetics - High-end consumers show resilience, with a focus on differentiated products from upstream manufacturers and mergers and acquisitions among downstream medical institutions to drive growth [3][5]. Investment Recommendations - Gold Jewelry: Favor brands with differentiated product strength and consumer insights, recommending Chao Hong Ji, Lao Pu Gold, and Chow Tai Fook, with beneficiaries including Chow Sang Sang [3][52]. - Retail E-commerce: Support offline retailers adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket, Ai Ying Shi, Ji Hong Co., and Sai Wei Times [3][82]. - Cosmetics: Highlight domestic brands that meet emotional value and safety innovation, recommending Mao Ge Ping, Pechoin, Shangmei Co., Juzi Biological, Wanmei Biological, and Runben Co. [3][52]. - Medical Aesthetics: Focus on differentiated medical aesthetic product manufacturers and expanding chain medical institutions, recommending Ai Mei Ke and Ke Di-B, with beneficiaries including Mei Li Tian Yuan Medical Health [3][52].

证券代码：603193 证券简称：润本股份 公告编号：2025-046 润本生物技术股份有限公司 关于使用部分暂时闲置募集资金进行现金管理 到期赎回的公告 截至本公告披露日，公司本次使用募集资金进行现金管理的情况如下： 1 | | 中国银行股 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2 | 份有限公司 | 结构 | 结构 | 13,200,000.00 | 3.09% | 202,263.78 | 2024/11/ | 2025/5/ | | | 广州珠江支 | 存款 | 存款 | | | | 12 | 12 | | | 行 | | | | | | | | | | 中国银行股 | | | | | | | | | 3 | 份有限公司 | 结构 | 结构 | 163,200,000.00 | 1.05% | 859,147.40 | 2024/11/ | 2025/5/ | | | 广州珠江支 | 存款 | 存款 | | | | 12 | 14 | | | 行 | | | | | | | | | | 中国银 ...

Market Overview - The personal care products sector increased by 1.02% on October 31, with稳健医疗 leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Key stocks in the personal care products sector showed varied performance, with the following notable changes: - 稳健医疗 (300888) closed at 41.30, up 2.00% with a trading volume of 100,200 shares and a turnover of 413 million yuan [1] - 洁雅股份 (301108) closed at 32.20, up 1.61% with a trading volume of 28,700 shares [1] - 豪悦护理 (6005009) closed at 32.60, up 1.46% with a trading volume of 16,900 shares [1] - 百亚股份 (003006) closed at 23.33, down 0.30% with a trading volume of 28,400 shares [1] Capital Flow - The personal care products sector experienced a net outflow of 45.69 million yuan from institutional investors, while retail investors saw a net inflow of 48.90 million yuan [2] - The following stocks had significant capital flow: - 稳健医疗 had a net inflow of 19.47 million yuan from institutional investors, but a net outflow from retail investors [3] - 登康口腔 saw a net inflow of 41.71 million yuan from speculative funds [3] - 豪悦护理 experienced a net outflow of 8.07 million yuan from institutional investors [3]

Core Viewpoint - Runben Co., Ltd. has shown a mixed performance in terms of stock trading and financial results, with significant fluctuations in financing activities and a notable increase in shareholder numbers, indicating potential investor interest and market volatility [1][2]. Financing Activities - On October 30, Runben Co., Ltd. experienced a financing buy-in of 4.78 million yuan, while financing repayments amounted to 10.72 million yuan, resulting in a net financing outflow of 5.94 million yuan [1]. - The total financing balance reached 314 million yuan, accounting for 11.58% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 300 shares were repaid, and 1,600 shares were sold short, with a total short sale value of 42,000 yuan, and the remaining short position stood at 9,100 shares, with a balance of 239,000 yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Runben Co., Ltd. reported a revenue of 1.238 billion yuan, reflecting a year-on-year growth of 19.28%, while the net profit attributable to shareholders was 266 million yuan, showing a modest increase of 1.98% [2]. - The company has distributed a total of 316 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 26,200, a rise of 57.33%, while the average number of circulating shares per shareholder decreased by 36.44% to 3,948 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Guotai Consumption Preferred Stock and the entry of new shareholders such as Southern CSI 1000 ETF and ICBC Consumption Service Mixed A [3].